| Section | Provisional content |
|---|---|
| SYCE1-related gametogenic failure — provisional mechanistic hypothesis evaluation (seed-only; retrieval blocked) | No tool-retrieved papers or citable context IDs were available in this session, so this report is seed-only, provisional, and not a fully cited 2023–2024 review. All publication-specific claims require manual verification against the seed PubMed records. |
| Retrieval limitation | Literature retrieval was blocked: repeated searches returned zero retrievable papers and zero citable contexts, preventing tool-grounded citation, figure review, and independent confirmation of publication-specific claims. |
| Executive judgment | **Partially supported (provisional).** The seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure through synaptonemal-complex dysfunction, but confidence is limited because the underlying papers were not retrievable for direct verification in this run. |
| Evidence matrix (seed PMIDs + PubMed URLs) | **PMID:25062452** — https://pubmed.ncbi.nlm.nih.gov/25062452/ — human familial genetics: homozygous nonsense SYCE1 variant reported in affected sisters with POI/primary amenorrhea. **PMID:32402064** — https://pubmed.ncbi.nlm.nih.gov/32402064/ — model evidence: no detectable SYCE1 protein and markedly reduced transcript, interpreted as infertility through defective homologous chromosome synapsis. **PMID:34718620** — https://pubmed.ncbi.nlm.nih.gov/34718620/ — in vitro/human cohort: SYCE1 variants reported to disrupt interaction with **SYCP1** and/or **C14ORF39/SIX6OS1**, affecting SC assembly and meiosis. **PMID:35718780** — https://pubmed.ncbi.nlm.nih.gov/35718780/ — human male infertility: SYCE1 CNVs reported in NOA with pachytene-stage arrest on H&E/IF. |
| Clinical spectrum by sex | **46,XX:** primary ovarian insufficiency / primary amenorrhea. **46,XY:** non-obstructive azoospermia with reported pachytene-stage spermatogenic arrest. Seed snippets support testis histology/IF evidence for pachytene arrest, but detailed endocrine data (e.g., FSH/AMH), ovarian imaging, follicle depletion, semen parameters, and full biopsy marker panels were not retrievable here. |
| Variant/inheritance summary | Provisional inheritance model: **autosomal recessive / biallelic**. Seed evidence mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting SYCE1 interactions, and **SYCE1 CNVs** in NOA. Exact zygosity/phasing, family counts, CNV breakpoints, segregation details, and ACMG/ClinVar classifications require manual verification from the seed papers. |
| Mechanistic causal chain | Provisional chain: **biallelic SYCE1 loss/damaging variant → reduced or absent SYCE1 → disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 → synaptonemal-complex central element assembly failure → homologous chromosome synapsis failure during meiotic prophase I → pachytene arrest/checkpoint activation → germ-cell depletion → 46,XX POI/primary amenorrhea or 46,XY NOA/spermatogenic arrest**. Human support appears strongest for phenotype and arrest endpoints; several intermediate steps likely rely on model or in vitro evidence. |
| Diagnostics/management implications | Provisional practice implications: include **SYCE1** on infertility/POI/NOA genetic testing panels with **CNV detection**; in 46,XY consider semen analysis, endocrine evaluation, and biopsy when clinically indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management likely follows standard care pathways: hormone replacement for POI as indicated, fertility counseling, donor-oocyte discussion for POI, and cautious consideration of micro-TESE/ICSI in NOA if sperm retrieval is feasible. |
| Ontology suggestions | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. |
| Knowledge gaps | Major gaps reflect the retrieval block: no full-text verification, no figure/table access, no confirmed hormone values or detailed histology, uncertain CNV zygosity/phasing, and limited ability to distinguish direct human evidence from mouse or in vitro inference. Direct evidence for checkpoint activation or apoptosis in human tissue remains especially uncertain. No newer 2023–2024 studies could be identified or prioritized in this environment. |
| Curator leads / verification checklist | After direct review of the seed PMIDs, consider updating the entry to note: (1) a core mechanism of **meiotic synaptonemal-complex central element assembly defect**; (2) dual-sex phenotype of **46,XX POI/primary amenorrhea** and **46,XY NOA/pachytene arrest**; (3) support for **loss-of-function and CNV** mechanisms; and (4) a partner-interaction mechanism involving **SYCP1** and **C14ORF39/SIX6OS1**. Verification tasks: confirm exact variant nomenclature and zygosity/phasing; verify segregation and family/case counts; extract 46,XX and 46,XY phenotype details including hormones, imaging, and biopsy findings; verify evidence for SYCE1 interaction defects; distinguish direct human evidence from mouse/in vitro inference; and manually check for any 2023–2024 updates. |


*Table: This table provides a concise, paste-ready provisional curation summary for SYCE1-related gametogenic failure based only on the seed PMIDs because no citable contexts were retrievable in the session. It captures the current mechanistic hypothesis, phenotype spectrum, variant evidence, and the main verification tasks needed before formal curation.*